CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BI 1569912Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2884 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (20)

Name (Synonyms) Correlation
D001997 Bronchopulmonary Dysplasia NIH 1.00
D008595 Menorrhagia NIH 1.00
D006929 Hyperaldosteronism NIH 1.00
D054559 Hyperphosphatemia NIH 1.00
D004314 Down Syndrome NIH 1.00
D000309 Adrenal Insufficiency NIH 1.00
D007008 Hypokalemia NIH 1.00
D009080 Mucocutaneous Lymph Node Syndrome NIH 0.71
D014552 Urinary Tract Infections NIH 0.71
D001289 Attention Deficit Disorder with Hyperactivity NIH 0.50
D006470 Hemorrhage NIH 0.50
D020141 Hemostatic Disorders NIH 0.27
D001778 Blood Coagulation Disorders NIH 0.27
D006973 Hypertension NIH 0.26
D004194 Disease NIH 0.17
D013577 Syndrome NIH 0.10
D003141 Communicable Diseases NIH 0.08
D007239 Infection NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (8)

Name (Synonyms) Correlation
HP:0002905 Hyperphosphatemia HPO 1.00
HP:0002900 Hypokalemia HPO 1.00
HP:0000846 Adrenal insufficiency HPO 1.00
HP:0000132 Menorrhagia HPO 1.00
HP:0000859 Hyperaldosteronism HPO 1.00
HP:0007018 Attention deficit hyperactivity disorder HPO 0.50
HP:0001928 Abnormality of coagulation HPO 0.27
HP:0000822 Hypertension HPO 0.26

There is one clinical trial.

Clinical Trials

1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1569912 in Healthy Male Subjects (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel-group Design) With an Additional Relative Bioavailability/ Food Effect Part (Open-label, Randomized, Three-way Crossover Design)

SRD-Part: To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses (SRD) of BI 1569912 BA/FE-Part: To investigate (a) the relative bioavailability (BA) of BI 1569912 and (b) the influence of food (FE) on the relative bioavailability of BI 1569912

NCT04445090 Healthy Drug: BI 1569912 Drug: Placebo

Primary Outcomes

Measure: SRD-part: % of subjects with drug-related adverse events

Time: up to 14 days

Measure: BA/FE-part: AUC0-tz (area under the concentration-time curve of BI 1569912 in plasma over the time interval from 0 to the last quantifiable data point)

Time: up to 4 days

Measure: BA/FE-part: Cmax (maximum measured concentration of BI 1569912 in plasma)

Time: up to 4 days

Secondary Outcomes

Measure: SRD-Part: AUC0-∞ (area under the concentration-time curve of BI 1569912 in plasma over the time interval from 0 extrapolated to infinity)

Time: up to 4 days

Measure: SRD-Part: Cmax (maximum measured concentration of BI 1569912 in plasma)

Time: up to 4 days

Measure: BA/FE-Part: AUC0-∞ (area under the concentration-time curve of BI 1569912 in plasma over the time interval from 0 extrapolated to infinity)

Time: up to 4 days

No related HPO nodes (Using clinical trials)